Welcome to our dedicated page for The Oncology Institute news (Ticker: TOI), a resource for investors and traders seeking the latest updates and insights on The Oncology Institute stock.
The Oncology Institute, Inc. (NASDAQ: TOI) is a leading cancer treatment and research organization focused on providing high-quality, value-based oncology care. Founded in 2007, TOI has established itself as a premier provider of comprehensive cancer treatment with over 70 clinic locations and a team exceeding 110 clinicians. The Institute offers a wide range of services, including infusion centers, outpatient blood transfusions, stem cell transplants, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling.
TOI operates in three primary segments: dispensary services, patient services, and clinical trials. The core of its operations lies in patient services, where personalized care plans are developed in collaboration with patients and their families to meet their unique needs. TOI’s mission is to advance oncology by making cutting-edge, evidence-based cancer care accessible within the community setting.
In recent developments, TOI announced a strategic partnership with WellBe Senior Medical to extend its High-Value Cancer Care Program to eligible patients in Illinois and Ohio. This initiative aims to enhance patient satisfaction, reduce acute care facility utilization, and support patients throughout their cancer treatment journey. Furthermore, TOI has joined Carrum Health’s Centers of Excellence network, providing high-value oncology care to non-metastatic breast cancer patients in Las Vegas.
TOI’s commitment to innovation in oncology care is also highlighted through its strategic collaboration with Healthly, a growing healthcare company focused on preventive medicine. Starting July 2024, TOI will offer its specialized cancer care services to Healthly’s affiliated patients and physicians across Southern California. This collaboration underscores TOI’s dedication to providing accessible and comprehensive cancer care in community settings.
Financially, TOI has a strong foundation supported by revenue generated predominantly from patient services. The Institute continues to expand its influence through partnerships and value-based care agreements, ensuring a sustainable and impactful presence in the oncology landscape. For more information, please visit theoncologyinstitute.com.
The Oncology Institute of Hope and Innovation (TOI) has acquired Women’s Cancer Care, expanding its services into California’s Central Valley. This clinic, established in 2001, is the only facility between San Francisco and Los Angeles specializing in breast and gynecologic oncology. The partnership aims to enhance medical resources and provide advanced care solutions to women in the region. TOI now employs over 80 clinicians and expands its presence with a team of more than 30 in Fresno, enhancing its commitment to value-based cancer care.
The Oncology Institute (TOI) will announce its Q1 2022 financial results on May 11, 2022, after market close, followed by a conference call at 5:00 p.m. ET. Investors can access the call by phone or via a webcast on TOI's Investor Relations website. TOI, established in 2007, focuses on value-based cancer care, serving approximately 1.6 million patients with a team of over 80 clinicians across 50 locations. For more details about the upcoming earnings report and the company's services, visit their official website.
The Oncology Institute of Hope and Innovation (NASDAQ: TOI) announced substantial achievements in the latest Oncology Care Model (OCM) performance period, saving Medicare nearly $9.5M since 2016 and exceeding target savings by $5.3M. The value-based oncology group showcased above-average quality performance, equating to savings of nearly $4,000 per patient episode. With over 80 employed clinicians and expanding services, TOI emphasizes better oncological outcomes while reducing costs for cancer patients across the U.S.
The Oncology Institute of Hope and Innovation (TOI) has appointed Mihir Shah as its new chief financial officer, effective immediately. With 15 years of experience in healthcare finance, Shah has previously served in CFO roles at organizations like Commonwealth Care Alliance and Apollo Medical Holdings. He will oversee critical functions such as Accounting, Finance, and Investor Relations, aiding TOI's strategic growth. Shah takes over from Scott Dalgleish, who will assist during the transition. TOI aims to enhance oncology care through its extensive services, benefiting around 1.6 million patients.
The Oncology Institute of Hope and Innovation (TOI) has expanded its presence in Southern California by opening a new clinic in Culver City on March 7, 2022, and enhancing its Riverside location on March 14, 2022. These expansions aim to improve access to quality oncology care. The Culver City clinic provides comprehensive medical services while the Riverside clinic tripled its infusion space to accommodate a growing patient population. TOI's commitment to advancing cancer care includes a strong emphasis on clinical trials and outpatient services, benefiting both patients and clinicians.
The Oncology Institute (NASDAQ: TOI) reported record revenue of $203 million for 2021, reflecting an 8.3% increase year-over-year.
For Q4, revenue reached $52 million, a 6.8% increase, despite a net loss of $10 million and significant SG&A expenses of $48 million due to growth investments.
Looking ahead to 2022, TOI anticipates revenue of $270 million to $310 million and projects managing between 1.75 million to 2.0 million lives under value-based contracts.
CERRITOS, Calif., March 8, 2022 – The Oncology Institute of Hope and Innovation (NASDAQ: TOI) announced that CEO Brad Hively will participate in the Jefferies Value-Based Healthcare Summit in Miami on March 14 at 1:40 pm EST. Hively has over 20 years of healthcare experience, transforming TOI into a leading oncology provider with over 50 clinics nationwide. The institute offers innovative, value-based cancer care to approximately 1.6 million patients. Investors can access a webcast of the event on the company’s website.
The Oncology Institute of Hope and Innovation (NASDAQ: TOI) has announced the promotions of Dr. Daniel Virnich to President and Dr. Matt Miller to Chief Operating Officer, effective March 15, 2022. These changes are part of a response to TOI's rapid growth. Dr. Virnich, who joined in 2020, will oversee various functions including Operations and Compliance, while Dr. Miller will manage all field and central operations nationally. Both leaders have previously driven tangible improvements in operational efficiency and patient satisfaction, positioning TOI for continued development in specialized oncology care.
The Oncology Institute (TOI) has established a value-based agreement with MaxHealth to deliver medical oncology care in Pinellas and Hillsborough Counties, beginning March 1, 2022. This partnership aims to enhance patient care through TOI's innovative oncology model, which includes over 170 clinical trials and comprehensive oncology services. The initiative targets expansion into neighboring counties, reflecting TOI's commitment to improving cancer care accessibility. Both organizations emphasize a shared goal of personalized patient care and satisfaction.
The Oncology Institute of Hope and Innovation (TOI) has entered a value-based agreement with MaxHealth to provide medical oncology care in Pinellas and Hillsborough Counties, Florida. This partnership, effective from March 1, 2022, aims to enhance cancer care access and quality through community-focused services, including clinical trials and stem cell transplants. TOI plans to expand this initiative to neighboring counties shortly. Both organizations emphasize a commitment to personalized care and improving patient satisfaction.
FAQ
What is the current stock price of The Oncology Institute (TOI)?
What is the market cap of The Oncology Institute (TOI)?
What services does The Oncology Institute, Inc. provide?
Where are The Oncology Institute's clinics located?
What recent partnerships has TOI announced?
How does TOI contribute to cancer research?
What is the focus of TOI's value-based care model?
How can patients access TOI's services?
What makes TOI's High-Value Cancer Care Program unique?
Who are the primary beneficiaries of TOI's services?
What role do clinical trials play at TOI?
How does TOI support patients financially?
